1191237-69-0
1191237-69-0
Chemical Structure
GS-441524
- CAS 番号: 1191237-69-0
- Formula:C12H13N5O4
- Molecular Weight:291.26
IUPAC Name: (2R,3R,4S,5R)-2-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-carbonitrile
InChIKey: BRDWIEOJOWJCLU-LTGWCKQJSA-N
SMILES: N#C[C@@]1(C2=CC=C3N2N=CN=C3N)O[C@H](CO)[C@@H](O)[C@H]1O
Biological Activity: GS-441524 is a potent, orally active and CNS-penetrant viral RNA-dependent RNA polymerase inhibitor. GS-441524 competes with natural nucleosides to block viral RNA transcription as an alternative substrate and RNA chain terminator. GS-441524 inhibits the replication of feline infectious peritonitis virus, African swine fever virus, and severe acute respiratory syndrome coronavirus 2. GS-441524 reduces viral RNA levels in cats. GS-441524 can be used in research related to feline infectious peritonitis, African swine fever, and coronavirus disease 2019 (COVID-19)[1][2][3][4][5].
| 製品番号 | 製品名 | 純度 | 製品説明 | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
GS-441524 | 99.89% | GS-441524 is a potent, orally active and CNS-penetrant viral RNA-dependent RNA polymerase inhibitor. GS-441524 competes with natural nucleosides to block viral RNA transcription as an alternative substrate and RNA chain terminator. GS-441524 inhibits the replication of feline infectious peritonitis virus, African swine fever virus, and severe acute respiratory syndrome coronavirus 2. GS-441524 reduces viral RNA levels in cats. GS-441524 can be used in research related to feline infectious peritonitis, African swine fever, and coronavirus disease 2019 (COVID-19). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
GS-441524 (Standard) | ≥98% | GS-441524 (Standard) is the analytical standard of GS-441524 (HY-103586). GS-441524 is a potent, orally active and CNS-penetrant viral RNA-dependent RNA polymerase inhibitor. GS-441524 competes with natural nucleosides to block viral RNA transcription as an alternative substrate and RNA chain terminator. GS-441524 inhibits the replication of feline infectious peritonitis virus, African swine fever virus, and severe acute respiratory syndrome coronavirus 2. GS-441524 reduces viral RNA levels in cats. GS-441524 can be used in research related to feline infectious peritonitis, African swine fever, and coronavirus disease 2019 (COVID-19). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
GS-441524-d | GS-441524-d is the deuterium labeled GS-441524 (HY-103586). GS-441524 is a potent, orally active and CNS-penetrant viral RNA-dependent RNA polymerase inhibitor. GS-441524 competes with natural nucleosides to block viral RNA transcription as an alternative substrate and RNA chain terminator. GS-441524 inhibits the replication of feline infectious peritonitis virus, African swine fever virus, and severe acute respiratory syndrome coronavirus 2. GS-441524 reduces viral RNA levels in cats. GS-441524 can be used in research related to feline infectious peritonitis, African swine fever, and coronavirus disease 2019 (COVID-19). | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
GS-441524 hydrochloride | 99.62% | GS-441524 hydrochloride is a potent, orally active and CNS-penetrant viral RNA-dependent RNA polymerase inhibitor. GS-441524 hydrochloride competes with natural nucleosides to block viral RNA transcription as an alternative substrate and RNA chain terminator. GS-441524 hydrochloride inhibits the replication of feline infectious peritonitis virus, African swine fever virus, and severe acute respiratory syndrome coronavirus 2. GS-441524 hydrochloride reduces viral RNA levels in cats. GS-441524 hydrochloride can be used in research related to feline infectious peritonitis, African swine fever, and coronavirus disease 2019 (COVID-19). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
GS-704277 | 98.77% | GS-704277 is an alanine metabolite of Remdesivir (HY-104077). GS-704277 is further hydrolyzed to GA-441524 (HY-103586) with antiviral activity. Remdesivir, a nucleoside analogue with effective antiviral activity, is highly effective in the control of SARS-CoV-2 (COVID-19) infection. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Remdesivir O-desphosphate acetonide impurity (Standard) | ≥98% | Remdesivir O-desphosphate acetonide impurity (Standard) is the analytical standard of Remdesivir O-desphosphate acetonide impurity. This product is intended for research and analytical applications. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Obeldesivir | 99.53% | Obeldesivir (ATV006) is a potent, orally active antiviral agent and ester proagents of GS-441524. Obeldesivir inhibits the replication of SARS-CoV-2 and its variants. Obeldesivir can be used for SARS-CoV-2 research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Antiviral agent 17 (Standard) | ≥98% | Antiviral agent 17 (Standard) is the analytical standard of Antiviral agent 17 (HY-146344). This product is intended for research and analytical applications. Antiviral agent 17 is an anti-infection agent. Antiviral agent 17 retains its antiviral effect in a human replicon assay (EC50 = 0.015 μM). Antiviral agent 17 results in good antiviral activity against murine norovirus with an EC50 of 7 nM. . Antiviral agent 17 has the potential for the research of infectious and malignant diseases. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
SHEN26 | 99.25% | SHEN26 (ATY014) is a potent and orally active RdRp inhibitor, with an IC50 for SARS-CoV-2 is 1.36 μM. SHEN26 is a 5’-cyclohexanecarboxylate derivative of GS-441524 (HY-103586). SHEN26 inhibits viral nucleic acid synthesis to achieve antiviral effects. SHEN26 can be used for the research of coronavirus disease 2019 (COVID-19). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
GS-6620 PM | GS-6620 PM (Compound 2) is an analog of 2′-C-methyl 4-aza-7,9-dideaza adenosine. 2′-C-methyl 4-aza-7,9-dideaza adenosine is an inhibitor of HCV replication in cell culture. GS-6620 PM can be used in the study of hepatitis C virus (HCV) infection. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
GS-646089 | GS-646089 is a broad-spectrum antiviral nucleoside analog that exhibits significant inhibitory activity against respiratory syncytial virus (RSV), human metapneumovirus (hMPV), rhinovirus (enterovirus) and enteroviruses. The IC50 of GS-646089 targeting RNA-dependent RNA polymerase (RdRp) ranges from 43 to 46 nM. GS-646089 blocks viral replication by being converted into a triphosphate metabolite intracellularly, which competes with ATP for incorporation into nascent RNA strands and acts as an immediate chain terminator. GS-646089 is the parent compound of the double prodrug GS-7682 (HY-161877), and is used in studies of acute respiratory viral infections and infections caused by related pathogens. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Remdesivir nucleoside monophosphate | 99.87% | Remdesivir nucleoside monophosphate is a metabolite of Remdesivir (HY-104077). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Murphy BG, et al. The nucleoside analog GS-441524 strongly inhibits feline infectious peritonitis (FIP) virus in tissue culture and experimental cat infection studies. Vet Microbiol. 2018 Jun;219:226-233. [Content Brief]
- [2]. Huang Z, et al. GS-441524 inhibits African swine fever virus infection in vitro. Antiviral Res. 2021;191:105081. [Content Brief]
- [3]. Rasmussen HB, et al. Nucleoside analog GS-441524: pharmacokinetics in different species, safety, and potential effectiveness against Covid-19. Pharmacol Res Perspect. 2022;10(2):e00945. [Content Brief]
- [4]. Pedersen NC, et al. Efficacy and safety of the nucleoside analog GS-441524 for treatment of cats with naturally occurring feline infectious peritonitis. J Feline Med Surg. 2019;21(4):271-281. [Content Brief]
- [5]. Coggins SJ, et al. Outcomes of treatment of cats with feline infectious peritonitis using parenterally administered remdesivir, with or without transition to orally administered GS-441524. J Vet Intern Med. 2023;37(5):1772-1783. [Content Brief]
